Skin Toxicity of Target Therapies, Immunotherapy and New Cancer Vaccines
Melisa Hunis and Adrian Hunis*
School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina
*Corresponding Author: Adrian Hunis, School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina.
June 19, 2023; Published: July 01, 2023
The new treatments for tumor diseases have been for about 20 years, a huge advance in medicine in general and oncology in particular. With target therapies, tyrosine kinase inhibitors, monoclonal antibodies, antitumor vaccines and new molecules under investigation, unthinkable responses are being achieved, for example, in melanoma, lung cancer, breast cancer and other tumors, what we do not fully know yet is the toxicity of these treatments.
The skin, the largest organ of the human being, is no stranger to this toxicity.
In this article we review this toxicity, its pathophysiology and its treatment.
Keywords: Lung Cancer; Breast Cancer; Oncology
- Lacouture ME. “Mechanisms of cutaneous toxicities to EGFR inhibitors”. Nature Reviews Cancer10 (2006): 803-812.
- Belum VR and Lacouture ME. “Dermatologic toxicities of cancer therapies”. Current Dermatology Reports 3 (2013): 171-182.
- Hwang SJ and Carlos G. “Immune checkpoint inhibitor-induced dermatologic toxicities: a review”. Journal of the American Academy of Dermatology 3 (2020): 675-688.
- Teulings HE., et al. “Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis”. Journal of Clinical Oncology7 (2015): 773-781.
- Su F., et al. “Molecular mechanisms of cutaneous toxicities of targeted therapies for hematological malignancies”. Journal of Dermatological Science3 (2017): 197-206.
- Salem JE., et al. “Immune checkpoint inhibitor-induced dermatologic adverse events”. Journal of the American Academy of Dermatology 1 (2019): 231-249.
- Freites-Martinez A., et al. “Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for dermatologists”. Journal of the American Academy of Dermatology 4 (2020): 844-857.
- Gonzalez-Velez M., et al. “Cutaneous adverse events of cancer immunotherapy: a single-center experience”. Case Reports in Oncological Medicine 2018 (2018): 3513262.
- Puzanov I., et al. “Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group”. Journal of Immunotherapy Cancer1 (2017): 95.
- Eilers RE Jr and Gandhi M. “Dermatologic toxicities of targeted therapies”. Oncology (Williston Park)3 (2013): 262-272.
- Haslam IS and Pittelkow MR. “Approach to the patient with drug-induced toxic epidermal necrolysis (TEN)”. Journal of the American Academy of Dermatology 5 (2012): e1-e12.
- Gonzalez-Rodriguez E., et al. “Skin toxicity from targeted therapy in advanced non-small-cell lung cancer: from EGFR inhibitors to immunotherapy”. Clinical and Translational Oncology2 (2019): 137-146.
- Hua C., et al. “Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab”. JAMA Dermatology1 (2016): 45-51.
- Osorio JC., et al. “Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer”. Annals of Oncology3 (2017): 583-589.
- Hunis AP., et al. “Cutaneous drug reactions associated with nivolumab treatment for metastatic NSCLC Case report”. Cancer therapy and Oncology International Journal2 (2018) 55578.